Table 2.
Compds. | 15 Days after Spraying | 28 Days after Spraying | ||
---|---|---|---|---|
Disease Index (%) | Curative Activity (%) c | Disease Index (%) | Protection Activity (%) c | |
2-(Methylsulfonyl)-5-(4-fluorophenyl)-1,3,4-oxadiazole | 57.63 ± 3.51 | 38.17 ± 2.15 A | 54.79 ± 2.78 | 41.82 ± 2.45 A |
Bismerthiazole a | 65.05 ± 2.26 | 30.21 ± 3.43 B | 58.85 ± 3.12 | 37.51 ± 2.54 C |
Thiodiazole copper b | 65.70 ± 2.73 | 29.51 ± 4.76 C | 70.08 ± 3.67 | 25.58 ± 2.42 B |
Untreated blank control | 93.21 ± 1.79 | 0 | 94.17 ± 2.55 | 0 |
a: 20% WP; b: 3% WP; c: Statistical analysis was conducted via the ANOVA method at a condition of equal variances assumed (p > 0.05) and equal variances not assumed (p < 0.05). Different capital letters indicate the values of control efficiency with significant difference among different treatment groups at p < 0.05.